EXECUTIVE ENGAGEMENTS
OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPETITORS
* Login for a full stack data experience
DATE
APR 2021
TABLES
168
PAGES
222
EDITION
17
PRICE
USD $5450
HIGHLIGHTS
SELECT PLAYERS
Bharat Serums and Vaccines Limited; Biotest AG; China Biologic Products, Inc.; CSL Limited; Grifols, S.A.; Hualan Biological Engineering Inc.; Kedrion S.p.A.; LFB Group; Octapharma AG; Shanghai RAAS Blood Products Co., Ltd.; Shire plc; Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
SEGMENTS
» Type (IgA, IgD, IgE, IgG, IgM) » Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications) » End-Use (Hospitals, Clinics, Homecare Settings) » Segment (Intravenous Immunoglobulin (IVIg))
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Immunoglobulins to See Steady Growth |
Recent Market Activity |
Intravenous Immunoglobulin - A Proliferating Biologic |
Application Areas - A Brief Review |
Market Outlook |
Growth Drivers and Market Challenges |
Competitive Scenario |
Grifols Continues to Consolidate Market Position |
CSL Sees Robust Growth in Immunoglobulin Franchise |
Shire Continues to Invest Big in Immunoglobulins |
Bivigam Changes Hands Consequent to Unexpected Turn of Events |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
Bharat Serums and Vaccines Limited (India) |
Biotest AG (Germany) |
China Biologic Products, Inc. (China) |
Guizhou Taibang Biological Products Co., Ltd (China) |
CSL Limited (Australia) |
Grifols, S.A. (Spain) |
Hualan Biological Engineering Inc. (China) |
Kedrion S.p.A. (Italy) |
LFB Group (France) |
Octapharma AG (Switzerland) |
Shanghai RAAS Blood Products Co., Ltd. (China) |
Shire plc (Ireland) |
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China) |
3. MARKET TRENDS & DRIVERS |
Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins |
Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market |
IVIg - The Mainstay of PI Therapy |
Subcutaneous IG Formulations Gain Therapeutic Foothold |
Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead |
Unsuccessful Clinical Trials for Alzheimer's - A major Setback for IVIg Market |
Synthetic Replacements to IVIg Therapy |
IVIg Therapy - Home-based vs. Outpatient Settings |
Per Capita Consumption Rate Varies Across Countries |
Favorable Reimbursement and High Usage make US the Largest Consumer |
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID |
Aging Global Population: Major Opportunity Indicator |
Improving Healthcare Expenditure to Foster Growth |
IV. COMPETITION |
Total Companies Profiled: 24 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com